Why and how should we simulate platform trials? Learnings from EU-PEARL
Abstract Background Platform trials are innovative clinical trials governed by a master protocol that allows for the evaluation of multiple investigational treatments that enter and leave the trial over time. Interest in platform trials has been steadily increasing over the last decade. Due to their...
Saved in:
Main Authors: | Elias Laurin Meyer, Tobias Mielke, Marta Bofill Roig, Michaela Maria Freitag, Peter Jacko, Pavla Krotka, Peter Mesenbrink, Tom Parke, Sonja Zehetmayer, Dario Zocholl, Franz König |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | BMC Medical Research Methodology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12874-024-02453-6 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
“Why should I?”
by: Anouk Broersma, et al.
Published: (2022-11-01) -
Resilience: why should we think with care?
by: Catia Gregoratti, et al.
Published: (2024-11-01) -
What is TEI Conformance, and Why Should You Care?
by: Lou Burnard
Published: (2018-12-01) -
Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints.
by: Elias Laurin Meyer, et al.
Published: (2023-01-01) -
What is Unifas and Why Should IFAS Faculty Enter Information into It?
by: Howard Ladewig, et al.
Published: (2006-05-01)